|
Are you receiving DocAlert messages? Just update (sync) your handheld or visit our help page to learn more.
Integrative Medicine
Editorial: Dr. Anne Meneghetti, Internist, Epocrates' senior medical editor
Some patients are delighted to learn that a solution to their medical problem might be found in a pill. Other patients are not. Patients attracted to alternative medicine often seek to understand the root cause of their condition and perhaps even discover meaning on the path to self-healing. Many physicians are perplexed when patients choose to forego proven standardized therapies from licensed practitioners and instead forge ahead into the untested territory of natural healing.
A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus
Objective: To determine the clinical effect of dietary supplementation with low-dose omega-3-polyunsaturated fatty acids on disease activity and endothelial function in patients with systemic lupus erythematosus.
Probiotics may improve irritable bowel syndrome
Bottom line: This systematic review/meta-analysis of randomized trials found a significant benefit of probiotics (number needed to treat [NNT] = 12) for improving symptoms of irritable bowel syndrome (IBS). Given the frequent difficulty in adequately treating this illness and the generally benign effects of probiotics, clinicians should strongly consider them for their patients with IBS. (LOE = 1a)
Probiotics decrease antibiotic-associated diarrhea in children
Bottom line: A probiotic consisting of several strains of a Lactobacillus species is effective in preventing prolonged diarrhea (greater than 48 hours) in children receiving antibiotics. It did not decrease the likelihood of developing diarrhea related to Clostridium difficile, although the study may have been too small to detect a benefit if one exist. (LOE = 1a)
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis
Results: 12 studies compared fibre with placebo or no treatment in 591 patients (relative risk of persistent symptoms 0.87, 95% confidence interval 0.76 to 1.00). This effect was limited to ispaghula (0.78, 0.63 to 0.96). Twenty-two trials compared antispasmodics with placebo in 1778 patients (0.68, 0.57 to 0.81). Various antispasmodics were studied, but otilonium (four trials, 435 patients, relative risk of persistent symptoms 0.55, 0.31 to 0.97) and hyoscine (three trials, 426 patients, 0.63, 0.51 to 0.78) showed consistent evidence of efficacy. Four trials compared peppermint oil with placebo in 392 patients (0.43, 0.32 to 0.59).
FDA MedWatch Safety Alerts
PML Cases Associated With Use of Raptiva
Zonisamide May Cause Metabolic Acidosis
Ongoing Safety Review of Clopidogrel: Studies on Genetic Differences and PPI Effects |